WPC
ANTH

White Pine Capital’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

White Pine Capital’s Portfolio ANTH Stock Details ANTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-4,375
Closed -$15K – 225
2017
Q1 		$15K Hold
4,375
– – 0.01% 212
2016
Q4 		$23K Buy
4,375
+1,250
+40% +$21.6K 0.01% 207
2016
Q3 		$79K Buy
+3,125
New +$78.8K 0.03% 207

Other funds holding ANTH

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

White Pine Capital's ANTH Position: Q2 2017 in Review

White Pine Capital sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q2 2017, closing a stake of 4,375 shares — an estimated $15K sold.

White Pine Capital first reported a position in ANTH in Q3 2016 and held it in 3 quarters. The position peaked at $79K in Q3 2016. 40 funds tracked by Wall St. Rank hold ANTH as of Q2 2017.

  • White Pine Capital reported no remaining Anthera Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • White Pine Capital sold 4,375 Anthera Pharmaceuticals, Inc. shares in Q2 2017, an estimated $15K.
  • White Pine Capital first reported a position in Anthera Pharmaceuticals, Inc. in Q3 2016 and held it in 3 quarters.
  • White Pine Capital's Anthera Pharmaceuticals, Inc. position peaked at $79K in Q3 2016.
  • 40 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q2 2017.

Based on White Pine Capital's 13F filing for Q2 2017, filed 10 Aug 2017.